Salts and solid forms of a monobactam antibiotic

US10919887B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Eric Aubin · Kembs, FR
• Anthony Casarez · Princeton, US
• Andreas Fisch · Basel, CH
• Zaixing Li · Yangpu District, CN
• Mika Lindvall · Emeryville, US
• Heinz Ernst Moser · San Mateo, US
• Michael Mutz · Glückstadt, DE
• Folkert Reck · Walnut Creek, US
• Bernd Ulrich Riebesehl · Soest, DE
• Marc Schoenhentz · Ungersheim, FR
• Vijay SETHURAMAN · Fremont, US
• Robert Lowell Simmons · San Francisco, US

Key dates

• Filing date: Sep 20, 2016
• Grant date: Feb 16, 2021
• Expiry date: May 6, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.